Sabiia Seb
PortuguêsEspañolEnglish
Embrapa
        Busca avançada

Botão Atualizar


Botão Atualizar

Ordenar por: 

RelevânciaAutorTítuloAnoImprime registros no formato resumido
Registros recuperados: 3
Primeira ... 1 ... Última
Imagem não selecionada

Imprime registro no formato completo
Sorafenib prevents liver fibrosis in a non-alcoholic steatohepatitis (NASH) rodent model BJMBR
Stefano,J.T.; Pereira,I.V.A.; Torres,M.M.; Bida,P.M.; Coelho,A.M.M.; Xerfan,M.P.; Cogliati,B.; Barbeiro,D.F.; Mazo,D.F.C.; Kubrusly,M.S.; D'Albuquerque,L.A.C.; Souza,H.P.; Carrilho,F.J.; Oliveira,C.P..
Liver fibrosis occurring as an outcome of non-alcoholic steatohepatitis (NASH) can precede the development of cirrhosis. We investigated the effects of sorafenib in preventing liver fibrosis in a rodent model of NASH. Adult Sprague-Dawley rats were fed a choline-deficient high-fat diet and exposed to diethylnitrosamine for 6 weeks. The NASH group (n=10) received vehicle and the sorafenib group (n=10) received 2.5 mg·kg-1·day-1 by gavage. A control group (n=4) received only standard diet and vehicle. Following treatment, animals were sacrificed and liver tissue was collected for histologic examination, mRNA isolation, and analysis of mitochondrial function. Genes related to fibrosis (MMP9, TIMP1, TIMP2), oxidative stress (HSP60, HSP90, GST), and...
Tipo: Info:eu-repo/semantics/article Palavras-chave: NASH; Fibrosis; Mitochondrial dysfunction; Sorafenib.
Ano: 2015 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2015000500408
Imagem não selecionada

Imprime registro no formato completo
Interleukin-27 augments the inhibitory effects of sorafenib on bladder cancer cells BJMBR
Cao,J.Y.; Yin,H.S.; Li,H.S.; Yu,X.Q.; Han,X..
Both sorafenib and interleukin-27 (IL-27) are antineoplastic drugs. This study aimed to investigate the synergistic effect of these two drugs on bladder cancer cells. HTB-9 and T24 cells were stimulated with IL-27 (50 ng/mL), sorafenib (2 μM) or the synergistic action of these two drugs. The cells without treatment acted as control. Cell proliferation, apoptosis and invasion were measured by bromodeoxyuridine assay, flow cytometry and modified Boyden chamber, respectively. Simultaneously, both modified Boyden chamber and scratch assay were used to assess cell migration. Finally, the phosphorylation levels of key kinases in the Akt/mechanistic target of rapamycin (mTOR)/mitogen-activated protein kinase (MAPK) pathway, and expression levels of matrix...
Tipo: Info:eu-repo/semantics/article Palavras-chave: Sorafenib; Interleukin 27; Proliferation; Apoptosis; Invasion; Akt/mTOR/MAPK.
Ano: 2017 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2017000800610
Imagem não selecionada

Imprime registro no formato completo
More than 10 years survival with sequential therapy in a patient with advanced renal cell carcinoma: a case report BJMBR
Yuan,J.L.; Wang,F.L.; Yi,X.M.; Qin,W.J.; Wu,G.J.; Huan,Y.; Yang,L.J.; Zhang,G.; Yu,L.; Zhang,Y.T.; Qin,R.L.; Tian,C.J..
Although radical nephrectomy alone is widely accepted as the standard of care in localized treatment for renal cell carcinoma (RCC), it is not sufficient for the treatment of metastatic RCC (mRCC), which invariably leads to an unfavorable outcome despite the use of multiple therapies. Currently, sequential targeted agents are recommended for the management of mRCC, but the optimal drug sequence is still debated. This case was a 57-year-old man with clear-cell mRCC who received multiple therapies following his first operation in 2003 and has survived for over 10 years with a satisfactory quality of life. The treatments given included several surgeries, immunotherapy, and sequentially administered sorafenib, sunitinib, and everolimus regimens. In the course...
Tipo: Info:eu-repo/semantics/report Palavras-chave: Metastatic renal cell carcinoma; Sequential therapy; Targeted anticancer agents; Sorafenib; Sunitinib; Immunotherapy.
Ano: 2015 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2015000100034
Registros recuperados: 3
Primeira ... 1 ... Última
 

Empresa Brasileira de Pesquisa Agropecuária - Embrapa
Todos os direitos reservados, conforme Lei n° 9.610
Política de Privacidade
Área restrita

Embrapa
Parque Estação Biológica - PqEB s/n°
Brasília, DF - Brasil - CEP 70770-901
Fone: (61) 3448-4433 - Fax: (61) 3448-4890 / 3448-4891 SAC: https://www.embrapa.br/fale-conosco

Valid HTML 4.01 Transitional